Canada markets close in 41 minutes

Aclarion, Inc. (ACON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2796-0.0022 (-0.78%)
As of 02:55PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.2818
Open0.2740
Bid0.2016 x 200
Ask0.3650 x 200
Day's Range0.2706 - 0.2894
52 Week Range0.2670 - 25.6000
Volume46,832
Avg. Volume1,456,869
Market Cap2M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-705.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
  • GlobeNewswire

    Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

    Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help

  • GlobeNewswire

    Aclarion Announces Closing of $3.0 Million Public Offering

    BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two commo

  • GlobeNewswire

    Aclarion Announces Pricing of $3.0 Million Public Offering

    BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two comm